Scarica l'app Stockscreener
3.39
0.59%
-0.02
Pre-mercato:
3.37
-0.02
-0.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVNC Giù?
Forum
Previsione
Revance Therapeutics Inc Borsa (RVNC) Ultime notizie
Revance Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your RightsRVNC - Morningstar
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Morningstar
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance LawsuitRVNC - Marketscreener.com
Class Action Filed Against Revance Therapeutics, Inc. - GlobeNewswire
Revance Therapeutics jumps after Teoxane offers $3.60 a share - MSN
Revance gains as it plans to enter talks with Teoxane on likely superior bid - MSN
Revance to Hold Talks With Teoxane on Takeover Proposal - MarketWatch
Revance gains as it plans to enter talks with Teoxane on likely superior bid (RVNC:NASDAQ) - Seeking Alpha
REVANCE ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Benzinga
Stockholder Notice: Robbins LLP Informs Stockholders of the Revance Therapeutics, Inc. Class Action Lawsuit - PR Newswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Law Offices of Frank R. Cruz Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action - Business Wire
Biotech Co. Revance Faces Suit After Tender Offer Weakens - Law360
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Teoxane Outbids Crown With New Revance Therapeutics Bid - Law360
Law Offices of Howard G. Smith Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action - Marketscreener.com
Revance Therapeutics Stock’s Retail Sentiment Muted Even As Teoxane Makes Better Offer Than Crown Labs - MSN
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Teoxane makes cash offer to buy Revance Therapeutics By Investing.com - Investing.com Canada
Revance Therapeutics Shares Rise as Teoxane Looks to Upend Crown Deal - MarketWatch
Revance Therapeutics jumps after Teoxane offers $3.60 a share (NASDAQ:RVNC) - Seeking Alpha
Teoxane makes cash offer to buy Revance Therapeutics - Investing.com
Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash - Yahoo Finance
Teoxane S.A. submitted a proposal to acquire all remaining stake in Revance Therapeutics, Inc. for $360 million. - Marketscreener.com
StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Revance Therapeutics (RVNC) Investors with Losses to Contact Firm’s Attorneys Before Feb. 8th Deadline in Securities Fraud Action - AccessWire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
HAGENS BERMAN, NATIONAL TRIAL ATTOREYS, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm’s Attorneys Now, Firm Investigating Possible Securities Law Violations - AccessWire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Down 23.1% in December - MarketBeat
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Given New $3.00 Price Target at Barclays - MarketBeat
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Franklin Resources Inc. - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - MarketBeat
Revance Therapeutics ticks higher as holder says Crown deal undervalues company - MSN
HighTower Advisors LLC Lowers Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Wellington Management Group LLP Invests $2.32 Million in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc.RVNC - Business Wire
Revance Therapeutics' SWOT analysis: tender offer shakes up specialty pharma stock - Investing.com
725,000 Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) Acquired by Oddo BHF Asset Management Sas - MarketBeat
Revance receives acquisition offer from Crown Laboratories for $3.10 per share - Yahoo Finance
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc.RVNC - Kilgore News Herald
Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Marketscreener.com
Crown Laboratories Commences Friendly Tender Offer for All Outst - GuruFocus.com
Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share - Marketscreener.com
Kirkland Advises Crown Laboratories on Amended Merger Agreement with Revance - Legal Desire News Network
Crown Labs announces merger with Revance Therapeutics - Johnson City Press
Revance Therapeutics' SWOT analysis: crown's tender offer lifts stock outlook By Investing.com - Investing.com Nigeria
Revance Therapeutics' SWOT analysis: crown's tender offer lifts stock outlook - Investing.com India
Crown Labs and Revance Therapeutics closer to merging - SuperTalk 92.9
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement - Happi
Mizuho Lowers Revance Therapeutics (NASDAQ:RVNC) Price Target to $3.10 - MarketBeat
0.08%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):